Document Detail

Comparative effects of once-daily molsidomine in coronary patients from two distinct European ethnicities.
MedLine Citation:
PMID:  19002405     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Molsidomine, a direct nitric oxide donor, is frequently used in several European countries for the treatment of stable angina. The aim of this study was to compare the effects of a new once-daily 16-mg dose formulation, Coruno (Therabel Pharmaceuticals, Loughrea, Ireland), in patients with stable angina belonging to two distinct European ethnicities. METHODS: A total of 261 Hungarian and 267 Polish patients took part in this multicenter, randomized, double-blind, placebo-controlled clinical trial. Exercise testing was performed after the first administration of molsidomine and repeated after a 2-week treatment. Frequency of anginal attacks, short-acting nitroderivative tablet consumption, and incidence of adverse events were also evaluated. RESULTS: Demographic and clinical characteristics were significantly different in Hungarian compared with Polish patients. Hungarian patients had a lower proportion of males, were shorter in stature, had less previous smoking experience, consumed more alcohol, had less severe coronary disease (electrocardiographic evidence, rate of anginal crises, and nitroderivative consumption), and higher exercise capacity. However, molsidomine-related improvement in exercise capacity at start of the study was similar in both cohorts. After a 2-week treatment, improvement was fully maintained in Polish and only minimally reduced in Hungarian patients. Furthermore, molsidomine reduced significantly more anginal episodes and nitroderivative consumption in the more severely affected Polish cohort. Proportions of patients reporting drug-related adverse events were similar on placebo and molsidomine in both cohorts. Most of the adverse events were not severe and resolved spontaneously. Less myocardial ischemia and gender (including height, a confounding covariate) acted positively and negatively, respectively, on the higher exercise capacity of Hungarian versus Polish patients. CONCLUSION: The once-daily 16-mg molsidomine formulation is effective and has good tolerability in both patient cohorts. Molsidomine does not induce any meaningful tolerance issues in Hungarian or Polish patients with stable angina, despite significant demographic and clinical disparities.
Roger Messin; Claude Dubois; Jean-Pierre Famaey
Related Documents :
3304705 - Nitrate tolerance: the lack of effect of n-acetylcysteine.
22425235 - Effects of exercise training on exercise capacity and quality of life in patients with ...
11527115 - Safety and efficacy of beta-blockers in the treatment of stable angina pectoris.
3111585 - Exertional gastro-oesophageal reflux: a mechanism for symptoms in patients with angina ...
4050695 - Prognostic significance of exercise-induced left ventricular dysfunction in chronic aor...
16361505 - Influence of harvest processes on pork loin and ham quality.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Advances in therapy     Volume:  25     ISSN:  1865-8652     ISO Abbreviation:  Adv Ther     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-25     Completed Date:  2010-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1200-14     Citation Subset:  T    
Therabel Pharma S.A./N.V., B-1180 Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina Pectoris / drug therapy*,  ethnology
Blood Pressure
Delayed-Action Preparations
Double-Blind Method
European Continental Ancestry Group*
Exercise Test
Health Behavior
Heart Rate
Medication Adherence
Middle Aged
Molsidomine / administration & dosage,  adverse effects,  therapeutic use*
Sex Factors
Vasodilator Agents / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Vasodilator Agents; 25717-80-0/Molsidomine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Atmospheric contamination by pesticides: Determination in the liquid, gaseous and particulate phases...
Next Document:  The role of erythropoietin in hemorrhagic shock-induced liver and renal injury in rats.